IS8329A - Kínólínafleiður og notkun þeirra í meðferð - Google Patents

Kínólínafleiður og notkun þeirra í meðferð

Info

Publication number: IS8329A
Authority: IS; Iceland
Prior art keywords: therapy; quinoline derivatives; quinoline; derivatives
Prior art date: 2003-07-28

Application number

IS8329A

Other languages

English (en)

Inventor

Ford Rhonan

Thompson Toby

Willis Paul

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-28

Filing date

2006-02-24

Publication date

2006-02-24

2006-02-24 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2006-02-24 Publication of IS8329A publication Critical patent/IS8329A/is

Links

229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Endocrinology (AREA)

IS8329A 2003-07-28 2006-02-24 Kínólínafleiður og notkun þeirra í meðferð IS8329A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0302139A SE0302139D0 (sv)	2003-07-28	2003-07-28	Novel compounds
PCT/SE2004/001144 WO2005009968A1 (en)	2003-07-28	2004-07-21	Quinoline derivates and their use in therapy

Publications (1)

Publication Number	Publication Date
IS8329A true IS8329A (is)	2006-02-24

Family

ID=27786663

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8329A IS8329A (is)	2003-07-28	2006-02-24	Kínólínafleiður og notkun þeirra í meðferð

Country Status (16)

Country	Link
US (1)	US20080058293A1 (is)
EP (1)	EP1651610A1 (is)
JP (1)	JP2007500187A (is)
KR (1)	KR20060054370A (is)
CN (1)	CN1829694A (is)
AU (1)	AU2004259615A1 (is)
BR (1)	BRPI0413094A (is)
CA (1)	CA2532154A1 (is)
CO (1)	CO5640110A2 (is)
IL (1)	IL172826A0 (is)
IS (1)	IS8329A (is)
MX (1)	MXPA06000882A (is)
RU (1)	RU2006102127A (is)
SE (1)	SE0302139D0 (is)
WO (1)	WO2005009968A1 (is)
ZA (1)	ZA200600820B (is)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0312609D0 (en)	2003-06-02	2003-07-09	Astrazeneca Ab	Novel compounds
WO2006110516A1 (en) *	2005-04-11	2006-10-19	Abbott Laboratories	Acylhydrazide p2x7 antagonists and uses thereof
WO2007109160A2 (en)	2006-03-16	2007-09-27	Renovis, Inc.	Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
US8546579B2 (en)	2006-03-16	2013-10-01	Evotec (Us) Inc.	Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
US20080058309A1 (en) *	2006-07-27	2008-03-06	Astrazeneca Ab	Novel Compounds 171
PE20091225A1 (es) *	2007-03-22	2009-09-16	Astrazeneca Ab	Derivados de quinolina como antagonistas del receptor p2x7
PE20091036A1 (es) *	2007-11-30	2009-08-15	Astrazeneca Ab	Derivado de quinolina como antagonista del receptor p2x7
US8232290B2 (en)	2008-03-25	2012-07-31	Affectis Pharmaceuticals Ag	P2X7R antagonists and their use
EP2243772B1 (en)	2009-04-14	2012-01-18	Affectis Pharmaceuticals AG	Novel P2X7R antagonists and their use
BR112012014180A2 (pt) *	2009-12-17	2015-09-15	Merck Sharp & Dohme	composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
AU2011252351A1 (en)	2010-05-14	2012-10-11	Affectis Pharmaceuticals Ag	Novel methods for the preparation of P2X7R antagonists
WO2012110190A1 (en)	2011-02-17	2012-08-23	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
WO2012163792A1 (en)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
WO2012163456A1 (en)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
KR101995088B1 (ko)	2011-07-22	2019-07-02	이도르시아 파마슈티컬스 리미티드	Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
MX336247B (es)	2012-01-20	2016-01-13	Actelion Pharmaceuticals Ltd	Derivados de amida heterociclicos como antagonistas del receptor p2x7.
US9718774B2 (en)	2012-12-12	2017-08-01	Idorsia Pharmaceuticals Ltd	Indole carboxamide derivatives as P2X7 receptor antagonist
AR094053A1 (es)	2012-12-18	2015-07-08	Actelion Pharmaceuticals Ltd	Derivados de indol carboxamida como antagonistas del receptor p2x₇
EP2956135B1 (en)	2013-01-22	2016-11-16	Actelion Pharmaceuticals Ltd.	Heterocyclic amide derivatives as p2x7 receptor antagonists
KR102220847B1 (ko)	2013-01-22	2021-02-26	이도르시아 파마슈티컬스 리미티드	Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
JP6692759B2 (ja) *	2014-06-05	2020-05-13	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	新規キノリン誘導体及び神経変性疾患におけるそれらの使用
PT3609868T (pt)	2017-03-13	2023-12-18	Raqualia Pharma Inc	Derivados de tetra-hidroquinolina como antagonistas do recetor p2x7
CN111777638B (zh) *	2020-05-22	2023-05-09	瀚海新拓(杭州)生物医药有限公司	喹啉类化合物、其制备方法、药物组合物和用途
CN114989082B (zh) *	2022-06-30	2024-06-21	华东理工大学	基于i价铜化物和三取代膦协同催化的羟氯喹的高效制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3471491A (en) *	1967-08-28	1969-10-07	Squibb & Sons Inc	Adamantyl-s-triazines
US3464998A (en) *	1968-03-04	1969-09-02	Searle & Co	Adamantyl esters and amides of pyridinecarboxylic acids
US4751292A (en) *	1985-07-02	1988-06-14	The Plant Cell Research Institute, Inc.	Adamantyl purines
US5643925A (en) *	1991-02-21	1997-07-01	Sankyo Company, Limited	Benzene derivatives having NGF production-promoting activity
ES2227769T3 (es) *	1994-05-27	2005-04-01	Glaxosmithkline S.P.A.	Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina.
AR004735A1 (es) *	1995-11-24	1999-03-10	Smithkline Beecham Spa	Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
TR199802385T2 (xx) *	1996-05-20	1999-04-21	Darwin Discovery Limited	TNF inhibit�rleri ve FDE-IV inhibit�rleri olarak kinolin karboksamidler.
GB0013737D0 (en) *	2000-06-07	2000-07-26	Astrazeneca Ab	Novel compounds
HUP0400390A2 (hu) *	2001-07-02	2004-09-28	Akzo Nobel N.V.	Tetrahidrokinolin-származékok és ezeket tartalmazó gyógyszerkészítmények
SE0103836D0 (sv) *	2001-11-16	2001-11-16	Astrazeneca Ab	Novel compounds

2003
- 2003-07-28 SE SE0302139A patent/SE0302139D0/xx unknown
2004
- 2004-07-21 US US10/566,320 patent/US20080058293A1/en not_active Abandoned
- 2004-07-21 MX MXPA06000882A patent/MXPA06000882A/es not_active Application Discontinuation
- 2004-07-21 KR KR1020067001966A patent/KR20060054370A/ko not_active Withdrawn
- 2004-07-21 WO PCT/SE2004/001144 patent/WO2005009968A1/en not_active Ceased
- 2004-07-21 JP JP2006521802A patent/JP2007500187A/ja not_active Withdrawn
- 2004-07-21 CN CNA2004800220985A patent/CN1829694A/zh active Pending
- 2004-07-21 CA CA002532154A patent/CA2532154A1/en not_active Abandoned
- 2004-07-21 AU AU2004259615A patent/AU2004259615A1/en not_active Abandoned
- 2004-07-21 EP EP04749180A patent/EP1651610A1/en not_active Withdrawn
- 2004-07-21 BR BRPI0413094-4A patent/BRPI0413094A/pt not_active Application Discontinuation
- 2004-07-21 RU RU2006102127/04A patent/RU2006102127A/ru not_active Application Discontinuation
2005
- 2005-12-26 IL IL172826A patent/IL172826A0/en unknown
2006
- 2006-01-25 CO CO06006724A patent/CO5640110A2/es not_active Application Discontinuation
- 2006-01-27 ZA ZA200600820A patent/ZA200600820B/en unknown
- 2006-02-24 IS IS8329A patent/IS8329A/is unknown

Also Published As

Publication number	Publication date
EP1651610A1 (en)	2006-05-03
CO5640110A2 (es)	2006-05-31
AU2004259615A1 (en)	2005-02-03
CN1829694A (zh)	2006-09-06
IL172826A0 (en)	2006-06-11
BRPI0413094A (pt)	2006-10-03
SE0302139D0 (sv)	2003-07-28
RU2006102127A (ru)	2006-08-27
MXPA06000882A (es)	2006-03-30
WO2005009968A1 (en)	2005-02-03
ZA200600820B (en)	2007-04-25
US20080058293A1 (en)	2008-03-06
JP2007500187A (ja)	2007-01-11
CA2532154A1 (en)	2005-02-03
KR20060054370A (ko)	2006-05-22

Publication	Publication Date	Title
IS8329A (is)	2006-02-24	Kínólínafleiður og notkun þeirra í meðferð
NO20052524D0 (no)	2005-05-26	Aminerte isofiavonoidderivater og anvendelse derav
DK1578755T3 (da)	2007-11-12	Phosphonooxyguinalinderivater og deres farmaceutiske anvendelse
IS6934A (is)	2003-08-29	Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20055204D0 (no)	2005-11-04	Derivater av piperidinyl- og pipemzinylalkylkarbamater, fremgangsmater for fremstilling derav og anvendelse av de samme i terapi
TWI349551B (en)	2011-10-01	Thiophenepyrimidinone derivatives and their use in therapy
DK1592686T3 (da)	2009-10-19	Gyrase-inhibitorer og anvendelser deraf
ZA200500680B (en)	2006-08-30	Quinoline derivatives and their use as mycrobacterial inhibitors
DK1465615T3 (da)	2012-11-12	Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
IS2485B (is)	2008-12-15	Fenýlsúlfónýl-1,3-díhýdró-2H-indól-2-ón afleiður,framleiðsla þeirra og notkun í meðferðarskyni
IS7701A (is)	2005-02-18	Arípíprazól samsett lyfjaform og aðferð
NO20054453L (no)	2005-11-29	P38 inhibitorer og fremgangsmater for anvendelse derav
DK1354888T3 (da)	2009-09-21	Glukopyranosyloxypyrazolderivater og anvendelse deraf i medikamenter
IS8146A (is)	2005-11-24	Setnar 3-alkýl og 3-alkenýl asetidín afleiður
NO20055246D0 (no)	2005-11-08	Heteroaromatisk pentasyklisk forbindelse og medisinsk anvendelse derav
IS2599B (is)	2010-04-15	3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
IL173398A0 (en)	2006-06-11	Pyridyl derivatives and their use as therapeutic agents
NO20053593D0 (no)	2005-07-22	Arylalkylkarbamat-derivater, fremgangsmate og anvendelse derav i terapi
DK1513835T3 (da)	2006-12-27	Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1708994T3 (da)	2007-11-26	Aryloxyalkylcarbamatderivater, fremstilling og anvendelse herfra inden for terapi
NO20054095D0 (no)	2005-09-02	Pyridyloksymetyl og benzioksazolazabicyklisk derivater
DK1525193T3 (da)	2008-04-28	Acylaminothiazolderivater, deres fremstilling og deres terapeutiske anvendelse
DK1556382T3 (da)	2008-10-06	3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
DK1663982T3 (da)	2008-03-17	Aminoquinolinderivater og deres anvendelse som adenosin-A3-ligander
IS6870A (is)	2003-07-09	2-arýlimínó-2,3-díhýdróþíasólafleiður, aðferðir til að framleiða þær og notkun þeirra í meðferð